This was the stock's second consecutive day of losses.

The stock's fall snapped a three-day winning streak.

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

At constant currency, sales were up 10%, with growth in its specialty-care unit driven by continued strength in anti-inflammatory drug Dupixent--jointly developed with Regeneron Pharmaceuticals ...

The sale of Sanofi's controlling stake in consumer health business Opella is expected to close in the second quarter at the earliest, completing its transition into a pure-play drug and vaccine ...

The expected growth in Dupixent’s revenue, particularly with its strong launch in COPD, provides a solid foundation for Regeneron’s future financial performance. Additionally, the company is ...

Analysts note that the possibility of Amgen launching Pavblu at risk is seen as low due to potential substantial damages if Regeneron's patent is upheld. Dupixent continues to be a significant ...

Analysts note that the possibility of Amgen launching Pavblu at risk is seen as low due to potential substantial damages if Regeneron's patent is upheld. Dupixent continues to be a significant growth ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...